ACRIN #6691 MONITORING AND PREDICTING BREAST CANCER NEOADJUVANT CHEMOTHERAPY

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 主要目的：DOSI将用于评价患者的反应 到化疗。这项临床试验的主要目的是确定是否 定量肿瘤组织光学指数（TOI）的DOSI测量的基线到治疗中期的变化可以预测接受术前新辅助化疗的乳腺癌患者的最终完全病理学反应。次要目的是研究在其他时间点获得的肿瘤生化成分的额外DOSI定量测量值、全范围病理学缓解（即完全、部分和无缓解）与任何相应成像测量值之间的相关性。DOSI和标准护理成像（例如，连续乳房X线照片、连续超声等）和/或所有MRI（例如，将收集ACRIN 6657或其他研究中共同入组的SOC成像或MRI成像）。 ACRIN #6691是由ACRIN赞助的第一个光学成像试验。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Main Objective: DOSI will be used to evaluate the patient's response to chemotherapy. The primary aim of this clinical trial is to determine whether the baseline to mid-therapy changes in the DOSI measurement of the quantitative tumor tissue optical index (TOI) can predict final complete pathologic response in breast cancer patients undergoing pre-surgical neoadjuvant chemotherapy. The secondary aims investigate the correlation between additional DOSI quantitative measurements of tumor biochemical composition obtained at other timepoints, the full range of pathologic response (i.e. complete, partial, and non-response) and any corresponding imaging measurements. DOSI and standard of care imaging (e.g. serial mammograms, serial ultrasounds, etc) and/or all MRI (e.g., SOC imaging or MRI imaging from co-enrollment in ACRIN 6657 or other studies) will be collected. ACRIN #6691 is the first optical imaging trial sponsored by ACRIN.